glp-1 colorectal cancer death risk study november 2025 GLP-1s in Oncology: Exploring Risks and Potential Benefits Ozempic, Wegovy might lower colon Could GLP-1s have an impact

S2CID 44318394

Furthermore, the EMA has withdrawn the weight loss medication rimonabant, a selective cannabinoid type 1 receptor antagonist, due to its reported links to increased risks of depression and suicide [70]

doi: 10.1513/pats.200708-137mg, 10

While prior gallbladder disease is not an absolute contraindication, it may influence the risk-benefit assessment

De Marinis YZ, Salehi A, Ward CE, Zhang Q, Abdulkader F, Bengtsson M, Braha O, Braun M, Ramracheya R, Amisten S, Habib AM, Moritoh Y, Zang E, Reimann F, Rosengren AH, Shibasaki T, Gribble F, Renstrm E, Seino S, Eliasson L, Rorsman P: GLP-1 inhibits and adrenaline stimulates glucagon release by differential modulation of N- and L-type Ca2+ channel-dependent exocytosis